ArticleJournal of psychiatric research2025
Comparative cardiac safety of haloperidol vs. chlorpromazine among people receiving hemodialysis.
Article in Journal of psychiatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSudden cardiac death (SCD) is > 20 times more likely among individuals receiving maintenance hemodialysis, relative to individuals not receiving hemodialysis. Typical antipsychotics increase risk for QT prolongation and SCD in the general population. The comparative cardiac safety of typical antipsychotics among individuals receiving hemodialysis is unknown.
methodsThis cohort study used an active comparator, new-user design to examine relative cardiac safety of the most frequently prescribed oral typical antipsychotics among individuals receiving outpatient maintenance hemodialysis (2007-2019). Data were obtained from the U.S Renal Data System. The primary outcome was 1-year risk of SCD. Inverse probability of treatment weighted Fine and Gray models estimated adjusted hazard ratios (aHR) and adjusted risk differences (aRDs), with 95 % confidence intervals (CIs), using an intention-to-treat approach. In primary analyses, deaths due to causes other than SCD were competing events.
resultsAmong 846,400 maintenance hemodialysis patients (2007-2019), haloperidol (n = 10,813) and chlorpromazine (n = 5800) were the most commonly prescribed oral typical antipsychotics. Among 6266 haloperidol and 3959 chlorpromazine new-users, 662 (9.9 %) and 234 (5.9 %), respectively, experienced SCD by 1-year. Compared to chlorpromazine new-use, Haloperidol new-use was associated with higher 1-year risk of SCD, aHR (95 % CI) = 1.38 (1.21,1.59); aRD (95 % CI) = 2.62 % (-0.27 %, 5.51 %). Analyses of additional cardiac outcomes yielded similar findings.
conclusionsHaloperidol was the most prescribed oral typical antipsychotic. Haloperidol new-use associated with a higher 1-year risk of SCD and other adverse cardiac outcomes compared to chlorpromazine new-use. Caution and close monitoring are warranted when newly prescribing haloperidol to individuals receiving hemodialysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.